ConductScience.org, home

Comparison · NCT04478071-0f4d7827

Vadadustat vs Placebo: Number of Participants With a Total Score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) Scale

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Vadadustat vs Placebo: Number of Participants With a Total Score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) Scale. Trial comparisons, record NCT04478071-0f4d7827. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04478071-0f4d7827

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7290.6660.784wilson
Risk in group 20.7040.6410.76wilson
Risk difference, group 1 minus group 20.0249-0.05950.109newcombe hybrid score
Risk ratio, group 1 over group 21.040.921.17log
Odds ratio, group 1 over group 21.130.7451.71log
Number needed to treat, for one more participant with the outcome on Vadadustat than on Placebo40.1from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Vadadustatvadadustat: Participants will receive vadadustat once daily for 14 days.156214OG000
Group 2Placeboplacebo: Participants will receive matching placebo once daily for 14 days.157223OG001

Outcome

Type
SECONDARY
Title
Number of Participants With a Total Score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) Scale
Description
Modified Sequential Organ Failure Assessment (MSOFA) scale:~Each of 5 organ systems is given a score of 0 to 4.The MSOFA scale total score is the sum of the score for the 5 organ systems. Total score ranges from 0 to 20, a higher score indicates a worse outcome. Discharged patients will be assigned a score of 0 and dead patients a score of 20.
Time frame
day 14
Population
Data were not collected for 2 participants in the vadadustat arm.

Source ClinicalTrials.gov

Trial

Title
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
NCT number
NCT04478071
Phases
PHASE2
Conditions
Acute Respiratory Distress Syndrome, Coronavirus Infection
Interventions
vadadustat, placebo
Lead sponsor
The University of Texas Health Science Center, Houston
Results first posted
2025-03-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04478071-0f4d7827